Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shot up 5.2% during trading on Monday . The company traded as high as $18.94 and last traded at $18.69. 839,585 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 1,080,003 shares. The stock had previously closed at $17.77.
A number of brokerages have recently commented on CAPR. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.60.
Get Our Latest Stock Analysis on Capricor Therapeutics
The company has a market capitalization of $626.15 million, a price-to-earnings ratio of -21.90 and a beta of 4.01. The company's fifty day simple moving average is $7.44 and its two-hundred day simple moving average is $6.07.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.13 EPS for the current year.
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm's stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 12.00% of the company's stock.
Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after buying an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $133,000. Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after buying an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.